TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 363347

Group type: EXPERIMENTAL
Intervention: Subdermal implants of levonorgestrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subdermal implants of norgestrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copper T200 (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Termination of use
Number of subjects: 0
Study: 28125158

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 26100581

Group type: EXPERIMENTAL
Intervention: Audiovisual family meetings (conference calling or Skype videoconferencing)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control meetings (traditional family meetings)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Audiovisual family meetings
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control meetings
Number of subjects: 88
Study: 24415390

Group type: EXPERIMENTAL
Intervention: Infant feeding intervention
Number of subjects: 698
Study: 22046961

Group type: EXPERIMENTAL
Intervention: BUD/FORM 160/4.5 μg, two inhalations twice daily
Number of subjects: 308

Group type: COMPARATOR
Intervention: BUD 200 μg, two inhalations twice daily
Number of subjects: 308
Study: 20011770

Group type: EXPERIMENTAL
Intervention: Metal-free, adhesively luted composite crowns (Artglass, Heraeus Kulzer)
Number of subjects: 114
Study: 17381400

Group type: EXPERIMENTAL
Intervention: Aerosolized ceftazidime
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 15347715

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 20 mg/kg every 12 hours for 48-72 hours
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hepatobiliary scintigraphy without UDCA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hepatobiliary scintigraphy after UDCA treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hepatobiliary scintigraphy
Number of subjects: 51
Study: 11152850

Group type: EXPERIMENTAL
Intervention: High-dose simvastatin
Number of subjects: 20
Study: 9539282

Group type: EXPERIMENTAL
Intervention: Continuous daily oral equine conjugated estrogen 0.625 mg (group A, N=10)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Daily transdermal 17beta‐estradiol 50 microg (group B, N=9)
Number of subjects: 19
Study: 8088918

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nitroglycerin (1 to 30 micrograms/min)
Number of subjects: 24
Study: 2263919

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (1:9, 0.5 watt/cm2 at 1 MHz, for 10 min) 3 days a week for 4 weeks, then twice weekly for 4 weeks, and once weekly for the following 4 weeks.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo-ultrasound (standard treatment with paste impregnated bandage and self-adhesive elastic bandage).
Number of subjects: 44
Study: 318825

Group type: EXPERIMENTAL
Intervention: Nandrolone phenpropionate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31083844

Group type: EXPERIMENTAL
Intervention: Interactive lecture
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 29
Study: 27826653

Group type: EXPERIMENTAL
Intervention: F_1 (Lactobacillus acidophilus and Lactobacillus reuteri)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: F_2 (Lactobacillus plantarum, Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (F_3)
Number of subjects: 60
Study: 25982297

Group type: EXPERIMENTAL
Intervention: FOLFIRI with panitumumab
Number of subjects: 182

Group type: COMPARATOR
Intervention: FOLFIRI with bevacizumab
Number of subjects: 182
Study: 23497350

Group type: EXPERIMENTAL
Intervention: medical nutrition therapy + advice to consume at least two pieces of fruit a day (high‐fruit)
Number of subjects: 63

Group type: COMPARATOR
Intervention: medical nutrition therapy + advice to consume no more than two pieces of fruit a day (low‐fruit)
Number of subjects: 63
Study: 21775131

Group type: EXPERIMENTAL
Intervention: SAG (Stop and Go) strategy
Number of subjects: 42

Group type: COMPARATOR
Intervention: 3DS (3 Days Switching) strategy
Number of subjects: 42
Study: 19635971

Group type: EXPERIMENTAL
Intervention: T-wave inversion through V(3) in ARVD patients without complete RBBB or incomplete RBBB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: T-wave inversion through V(3) in ARVD patients with incomplete RBBB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: T-wave inversion through V(4) in ARVD patients with complete RBBB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: r'/s ratio in V(1) <1 in ARVD patients with complete RBBB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: r'/s ratio <1 in ARVD patients with complete RBBB
Number of subjects: 100
Study: 16948990

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (1.5 g intravenous for 20 minutes)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (intravenous solution for 20 minutes)
Number of subjects: 24
Study: 16586343

Group type: EXPERIMENTAL
Intervention: Soccer-specific intermittent exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both exercise types
Number of subjects: 8
Study: 14613735

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day) for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10586340

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily orally (n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Formestane 250 mg once every two weeks by intramuscular injection (n = 31)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Formestane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anastrozole and Formestane
Number of subjects: 60
Study: 8757378

Group type: COMPARATOR
Intervention: Hepatic vascular exclusion (HVE)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Portal triad clamping (PTC)
Number of subjects: 52
Study: 1657128

Group type: EXPERIMENTAL
Intervention: Single infusion of MAb C23 (5 to 80 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Three infusions of MAb C23 (60, 20, and 20 mg at 1-week intervals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 20
Study: 6961425

Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B-6) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30442217

Group type: EXPERIMENTAL
Intervention: Group psychological treatment program (8 one-hour sessions, cognitive-behavioral approach)
Number of subjects: 51
Study: 27122490

Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of 500 IU hCG (n=7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Embryo culture media vehicle (n=8)
Number of subjects: 15
Study: 26059781

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (50 U per axilla)
Number of subjects: 141
Study: 24036742

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nitrous oxide associated with oxygen
Number of subjects: 28
Study: 20372671

Group type: EXPERIMENTAL
Intervention: Brief individual motivational interview
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Adapted school lecture
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301
Study: 18462269

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV), frequency: 26 Hz, duration: 10 sets of 60 seconds with 60 seconds rest
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON), no WBV stimulation
Number of subjects: 10
Study: 16806871

Group type: EXPERIMENTAL
Intervention: Omega-3 acid ethyl esters at 62.5% concentration
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Omega-3 acid ethyl esters at 80% concentration
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Omega-3 acid ethyl esters at 85% concentration
Number of subjects: 101
Study: 14533656

Group type: EXPERIMENTAL
Intervention: Symptom days
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Percentage of predicted FEV1
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Asthma severity, use of peak expiratory flow rate meters, younger age, low-income status, nonwhite race, longer duration of asthma
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Total annual asthma-related cost
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Medicines
Number of subjects: 638
Study: 10835439

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 40000
Study: 9355594

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 87
Study: 8225149

Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2-0.4 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Captopril (25-50 mg daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 50
Study: 3517926

Group type: EXPERIMENTAL
Intervention: Stanozolol 5 mg twice daily for six months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30348178

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (5 mg.kg-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 12
Study: 27996026

Group type: EXPERIMENTAL
Intervention: Public reporting of prescriptions
Number of subjects: 20
Study: 25509236

Group type: EXPERIMENTAL
Intervention: 1 g intravenous (IV) paracetamol 20 min before the operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 cc normal saline (placebo) 20 min before the operation
Number of subjects: 60
Study: 22938071

Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional Language Therapy (CLT)
Number of subjects: 18
Study: 20712134

Group type: EXPERIMENTAL
Intervention: Test formulation of betahistine (16 mg tablet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation of betahistine (16 mg tablet)
Number of subjects: 0
Study: 18230389

Group type: COMPARATOR
Intervention: Clobetasol 0.05% ointment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 30
Study: 15702296

Group type: EXPERIMENTAL
Intervention: Computer-generated delineation of a plan optimization volume (POV) and an irradiated volume (IV) using a computer algorithm with constrained matrix inversion (CMI) as optimization method.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human heuristics using only the central slice (2-D) for optimization.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human heuristics using the whole set of CT slices (3-D) for optimization.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard planning procedure at Ghent University Hospital, Belgium.
Number of subjects: 0
Study: 12812866

Group type: EXPERIMENTAL
Intervention: Insulin levels of 35 microU/ml
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Insulin levels of 85 microU/ml
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Insulin levels of 25 microU/ml
Number of subjects: 37
Study: 10827410

Group type: EXPERIMENTAL
Intervention: 0.5 x 10(6) IU/m(2) of rIFN‐gamma (low‐dose group)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1.5 x 10(6) IU/m(2) of rIFN‐gamma (high‐dose group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: rIFN‐gamma therapy (both dosages)
Number of subjects: 51
Study: 10163997

Group type: EXPERIMENTAL
Intervention: Utility-based health status measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other forms of health status measures
Number of subjects: 0
Study: 1655353

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nonachlazine
Number of subjects: 138
Study: 6409006

Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study: 30975111

Group type: EXPERIMENTAL
Intervention: Health and physical fitness-related program (IG-run)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Health and physical fitness-related program (IG-game play)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Regular physical education lessons (CG-run)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Regular physical education lessons (CG-game play)
Number of subjects: 48
Study: 30397721

Group type: EXPERIMENTAL
Intervention: PSA-based prostate cancer screening (European Randomized Study for Screening of Prostate Cancer - ERSPC)
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Risk-adapted screening intervals based on baseline PSA level assessment at a young age (40-50)
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Risk-adapted prostate cancer screening (PROBASE study)
Number of subjects: 60000
Study: 25965997

Group type: EXPERIMENTAL
Intervention: Humorous demonstration group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control demonstration group
Number of subjects: 53
Study: 24656715

Group type: EXPERIMENTAL
Intervention: Hip strength measurements and trunk endurance assessment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Trunk side‐plank endurance
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isometric strength measurements
Number of subjects: 38
Study: 22205315

Group type: EXPERIMENTAL
Intervention: Entrée portion sizes of 100, 160, 220, 280, 340, and 400 g
Number of subjects: 17
Study: 19439363

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 14911

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14911

Group type: EXPERIMENTAL
Intervention: Overall (all indications)
Number of subjects: 14911

Group type: EXPERIMENTAL
Intervention: Paroxetine in MDD
Number of subjects: 14911
Study: 18598831

Group type: EXPERIMENTAL
Intervention: Sulfurous‐arsenical‐ferruginous thermal water nasal irrigation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution nasal irrigation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both irrigation modalities
Number of subjects: 80
Study: 15888638

Group type: EXPERIMENTAL
Intervention: Patient Navigator (PN+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Patient Navigator (PN-)
Number of subjects: 0
Study: 11924590

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.12% with 11% ethanol (group 1; CHX‐A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.12% without alcohol (group 2; CHX‐NA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (group 3; P)
Number of subjects: 96
Study: 10656954

Group type: EXPERIMENTAL
Intervention: Open cholecystectomy (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Videolaparoscopic cholecystectomy (group B)
Number of subjects: 20
Study: 8862298

Group type: EXPERIMENTAL
Intervention: Triple-matched defects in the upper plus middle zones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple-matched defects in the lower zones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple-matched defects involving 25-50% of a zone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smaller or larger triple-matched defects
Number of subjects: 0
Study: 1538447

Group type: EXPERIMENTAL
Intervention: Transurethral polytetrafluoroethylene (Teflon)-coated latex catheter
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Transurethral polyvinylchloride catheter
Number of subjects: 344

Group type: COMPARATOR
Intervention: Suprapubic polyvinylchloride catheter
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 344

Group type: COMPARATOR
Intervention: Suprapubic drainage group
Number of subjects: 344
Study: 6238829

Group type: EXPERIMENTAL
Intervention: mianserin 10 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: amitriptyline 10 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: amitriptyline 50 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: zimeldine 200 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ethanol 1 g/kg bodyweight
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 29220609

Group type: EXPERIMENTAL
Intervention: SSF‐Assessment Group Therapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual Assessment Group Therapy
Number of subjects: 141
Study: 29516964

Group type: EXPERIMENTAL
Intervention: Rendezvous therapy (radiotherapy with local delivery of nimustine and oral temozolomide)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard therapy (radiotherapy with concomitant and adjuvant temozolomide)
Number of subjects: 71
Study: 27397608

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (n = 677 boys)
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Delayed intervention group (n = 658 girls)
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (n = 613 girls)
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Delayed intervention group (n = 687 boys)
Number of subjects: 1700
Study: 24647023

Group type: EXPERIMENTAL
Intervention: Metronidazole (10-day course, oral)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 96
Study: 22017387

Group type: EXPERIMENTAL
Intervention: Complex anthroposophic remedy (Apis regina tota GL D4, Argentum metallicum D5, Ovaria bovis GL D4), 3 × 10 globuli daily for 12 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Complex remedy for 24 consecutive weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group 1 (R/R/P)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group 2 (P/R/R)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group 3 (R/P/R)
Number of subjects: 102
Study: 19846181

Group type: EXPERIMENTAL
Intervention: small carbohydrate (CH)-rich meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: large carbohydrate (CH)-rich meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: fat-rich meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: more carbohydrate (CH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: control (well-controlled patients with diabetes)
Number of subjects: 24
Study: 17622710

Group type: EXPERIMENTAL
Intervention: 4 different dialyzers differing in biocompatibility and flux, used for 4 weeks
Number of subjects: 15
Study: 16245418

Group type: EXPERIMENTAL
Intervention: Fenspiride 160 mg/day for 6 months
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 11832706

Group type: EXPERIMENTAL
Intervention: Hands-on training (low fidelity model)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hands-on training (high fidelity model)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Didactic session
Number of subjects: 40
Study: 12476070

Group type: EXPERIMENTAL
Intervention: Massage therapy for 14 days
Number of subjects: 21
Study: 9829492

Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy (Ferric saccharate, 100 mg dose, administered postdialysis on five consecutive dialysis sessions for 2 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid therapy (300 mg dose, administered thrice a week for 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Control I and Control II, haematocrit > 30%, no adjuvant therapy)
Number of subjects: 50
Study: 8137272

Group type: EXPERIMENTAL
Intervention: Detection of oncogene mutations in sputum using a polymerase chain reaction-based assay.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Earliest detection of a clonal population of cancer cells in sputum.
Number of subjects: 15
Study: 2667926

Group type: EXPERIMENTAL
Intervention: Continuous basal-rate intravenous insulin infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single daily injections of ultralente insulin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single daily injections of lente insulin
Number of subjects: 10
Study: 996681

Group type: EXPERIMENTAL
Intervention: 220 mg zinc sulphate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 ml bicitropeptide
Number of subjects: 0
Study: 7014104

Group type: EXPERIMENTAL
Intervention: Amineptine (mean 180 mg, range 100-300 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clomipramine (mean 84 mg, range 50-150 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 62
Study: 31356483

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation exercises in addition to repositioning maneuvers (experimental group, n = 17)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Repositioning maneuvers only (control group, n = 15)
Number of subjects: 32
Study: 29356603

Group type: EXPERIMENTAL
Intervention: 25 mg dexketoprofen trometamol (DKT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 500 mg vitamin C (PLACEBO)
Number of subjects: 100
Study: 27821382

Group type: EXPERIMENTAL
Intervention: Intravenous eculizumab (900 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 24965720

Group type: EXPERIMENTAL
Intervention: NHA-Burden Prognostic tool
Number of subjects: 1610

Group type: EXPERIMENTAL
Intervention: NHA-Depression Prognostic tool
Number of subjects: 1610
Study: 22168326

Group type: COMPARATOR
Intervention: 0.1% topical adapalene gel for 4 weeks (Group A)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 0.1% topical adapalene gel and 600 mg oral faropenem for 2 weeks followed by 0.1% topical adapalene gel alone for 2 weeks (Group B)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 0.1% topical adapalene gel and 600 mg oral faropenem for 4 weeks (Group C)
Number of subjects: 158
Study: 19937983

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Short-incision open donor nephrectomy (ODN)
Number of subjects: 84